On June 9, 2021 Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, reported that company management will present its corporate highlights at the following investor conferences in June (Press release, Gamida Cell, JUN 9, 2021, View Source [SID1234583781]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

JMP Securities Life Sciences Conference, June 16-17, 2021. In a fireside chat at 12:30 p.m. ET on June 16, 2021, management will discuss a corporate overview for 2021 with a special focus on multiple growth opportunities driven by advances in the development of omidubicel, a potentially life-saving NAM-enabled cell therapy with positive Phase 3 clinical data, and based on encouraging preliminary clinical results, NAM-enabled natural killer (NK) cell immunotherapies including GDA-201.
A.G.P. Summer Healthcare Symposium, June 17, 2021. The company will present its 2021 corporate highlights to investors in one-on-one meetings on June 17, 2021.
In the fourth quarter of 2021, Gamida Cell is targeting a BLA submission for omidubicel, the first potential approval of a cell therapy for blood cancer patients in need of an allogeneic bone marrow transplant. In the second half of 2021, the Company is planning an IND submission to support the initiation of a Phase 1/2 clinical study of cryopreserved, off-the-shelf GDA-201 in patients with follicular and diffuse large b-cell lymphomas.

A live webcast of the JMP Securities fireside chat will be available on the "Investors & Media" section of Gamida Cell’s website at www.gamida-cell.com, and will be available for at least 14 days following the event.

On June 9, 2021 Vernalis, a fully owned subsidiary of HitGen Inc., and Servier reported the achievement of one research and one pre-clinical milestone in their oncology drug discovery collaboration, triggering undisclosed milestone payments to Vernalis (Press release, Vernalis, JUN 9, 2021, View Source;utm_medium=rss&utm_campaign=vernalis-and-servier-achieve-two-milestones-in-their-oncology-drug-discovery-collaboration [SID1234583798]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Vernalis and Servier’s partnership has been running successfully since 2007. The collaboration takes advantage of Vernalis’ proprietary fragment and structure-based drug discovery platform, and of Servier’s expertise in medicinal chemistry, cancer biology and pharmacology to bring innovation in oncology one step further.

The collaboration focuses on complicated molecular targets, some of which, like Mcl-1, were considered as undruggable until recently. Previously, has been announced the discovery of the first generation of Mcl-1 inhibitors which have entered clinical trials (published in Nature, 538: 477; ACS Omega, 4: 8892; J. Med. Chem., 63: 13762). The pre-clinical milestone announced today corresponds to a second generation, selective Mcl-1 inhibitor entering pre-clinical development. The research milestone relates to success in early drug discovery against another challenging, promising but undisclosed target.

"These milestones further validate our fragment and structure-based drug discovery platform as well as the strength and success of our relationship with Servier. We look forward to working together to develop exciting new cancer treatment opportunities to add to the already disclosed success in targeting Bcl-2 and Mcl-1", commented James Murray, Research Director at Vernalis.

"These research and clinical milestones are the result of highly interactive joint efforts between chemists, biochemists and biologists from both companies and hopefully will lead to new treatments for cancer patients," Olivier Geneste, Head of Apoptosis and Targeted Therapies Research Program in Oncology at Servier commented. "They illustrate well the innovative freedom that Servier has kept through its important investment in R&D."

Under the current agreement, Vernalis receives fees for work undertaken as well as research and development milestones and potentially royalties on sales.

On June 9, 2021 RemeGen reported that National Medical Products Administration(NMPA), China’s first independently developed antibody-drug conjugate (ADC)- Disitamab vedotin (trade name: Aidexi, research code: RC48) was approved to market for the treatment of locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) with HER2 over-expression in patients who have received at least two types of systemic chemotherapy (Press release, RemeGen, JUN 9, 2021, View Source [SID1234594764]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The approval of Disitamab vedotin has broken the situation that there is no original domestic new drug in the field of ADC drugs, and filled the gap in the global post-line treatment of patients with HER2 over-expression of gastric cancer. It is a milestone in the history of independent innovation of biological medicine in China.

Prior to this, the world’s first dual-target treatment for systemic lupus erythematosus (SLE) biological medicine Telitacicept was approved by the NMPA on March 9. In less than 6 months, two world-class novel drugs have been approved, RemeGen shows its strength in research and development, and aims to become a leader in the China bio-pharmaceutical industry.

On June 9, 2021 Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, reported that Ryan Spencer, Chief Executive Officer, will present virtually at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021 at 3:50 p.m. E.T (Press release, Dynavax Technologies, JUN 9, 2021, View Source [SID1234583749]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company’s website at View Source

On June 9, 2021 MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company that utilizes the latest biotechnology to discover and deliver novel medicines, reported clinical data from a Phase 1b study of zandelisib, an investigational selective phosphatidylinositol 3-kinase delta ("PI3K") inhibitor in clinical development for the treatment of B-cell malignancies, and the trial design of COASTAL, a Phase 3 study of zandelisib in combination with rituximab, will be highlighted in poster presentations at the 16th International Conference on Malignant Lymphoma (16-ICML) to be held June 18 – 22, 2021 (Press release, Kyowa Hakko Kirin, JUN 9, 2021, View Source [SID1234583766]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the two e-poster presentations are included below:

Title: Zandelisib, a PI3Kδ Inhibitor on Intermittent Schedule (IS) in Follicular Lymphoma Patients who Progressed within 24 Months of First-Line Chemoimmunotherapy (POD24)
Authors: John Pagel, et. al.
Abstract ID: 113

Title: COASTAL: A Phase 3 Study of the PI3Kδ Inhibitor Zandelisib with Rituximab (R) versus Immunochemotherapy in Patients with Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma (iNHL)
Authors: Wojciech Jurczak, et. al.
Abstract ID: 262

The abstracts are available on the Wiley Online Library website. The e-poster presentations will be available on the MEI Pharma website on June 18, 2021.